Recent research have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopaminergic neurotransmission. While GIP agonists are widely employed for managing type 2 diabetes, their unexpected effects on motivation circuits, specifically mediated by